Phase 2 Inovio COVID-19 Vaccine

Site Image

Study Overview

Phase 2/3 study of INO-4800 DNA vaccine for SARS-CoV-2 to assess safety, efficacy & immunogenicity of vaccine in health volunteers at high risk for SARS-CoV-2 exposure. INO-4800 1.0mg or placebo given by intradermal injection followed by electroporation using CELLECTRA2000 investigational device at Day 0 and Day 28. Procedures include physicals, biospecimen collection and subject diaries over 8 outpatient visits plus phone calls.

Study Description

If you agree to join the study, you will be asked to complete the following research procedures: 

Screening, vaccination visits (2 of them) and collection of medical information as well as blood to evaluate the safety and the ability of the vaccine to make an immune response against the coronavirus.
Follow-up visits via phone and in-person
Your participation will last for about 13 months. 

  • Study Identifier: 843500

Recruitment Status

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email